Sicca to Lymphoma: Sjogren Syndrome

Laura Heretiu, Denisa Predeţeanu

Department of Internal Medicine and Rheumatology, “Sf. Maria” Clinical Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania.

DOI: 10.4236/ojra.2013.31005                

Abstract

Sjogren Syndrome (SS) is an autoimmune disease characterized by a lymphocytic infiltration of exocrine glands. This abnormality leads to the destruction of these glands with the clinical expression of the sicca syndrome (dry eyes and dry mouth). Usually Sjogren Syndrome follows a non-aggressive course, but patients suffering from this disease have a very high risk of developing malignant lymphoma (MALT). The evolution from benign lymphocytic infiltration characteristic of Sjogren Syndrome to malignant lymphoma (usually MALT subtype) is a multistep process [1-3]. We present the case of 35 years old woman admitted to “Sf. Maria” Clinical Hospital—Bucharest, Romania, in the Rheumatology Department in May 2011, representative for the diagnosis difficulties as well as for the unfortunate evolution. She was diagnosed with primary Sjogren Syndrome in 2004. The first symptoms of the disease, dry eyes and dry mouth, appeared in 2000 but they were undermined by some hematological disorders, as the patient had a low white blood cell count at the biological evaluation. Four years later, when the diagnosis of Sjogren Syndrome was set, she already had some negative prognosis factors. In the end, the disease had an unfavorable outcome, as the patient developed non-Hodgkin malignant lymphoma for an unfortunate evolution.

Keywords

Autoimmune Disease; Prognosis Factors; Non Hodgkin Lymphoma

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	N. M. Van Mello, S. R. Pillemer, P. P. Tak, et al., “B Cell MALT Lymphoma Diagnosed by Labial Minor Salivarygland Biopsy in Patients Screened for Sjo¨Gren’s Syndrome,” Annals of Rheumatic Disease, Vol. 64, No. 3, 2005, pp. 471-473. doi:10.1136/ard.2004.022707
[2]	R. Ionescu, et al., “Esentialul in Reumatologie,” Cap.19, 2nd Revised Edition, Daniela Opris, Amaltea, Bucharest, 2007, pp. 270-279.
[3]	B. Royer , D. C. Hatem and J. Sibilia, “Lymphomas in Patients with Sjogren’s Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated with Viruses,” Blood, 15, Vol. 90, No. 2, 1997, pp. 766-775.
[4]	A. V. Miller, S. K. M. Ranatunga, M. L. Francis, et al., Medscape Reference (Durgs, Diseases &Procedures), Last Updated 31 October 2011.
[5]	M. Garcia Carrasco, S. Fuentes Alexandro and R. O. Escarcega, “Pathophysiology of Sjogren’s Syndrome,” Archives of Medical Research, Vol. 37, No. 8, 2006, pp. 921-932. doi:10.1016/j.arcmed.2006.08.002
[6]	J. Maggie, “A Short Review of the Pathogenesis of Sjogren Syndrome,” Larche Autoimmunity Reviews, Vol. 5, No. 2, 2006, pp. 132-135.
[7]	P. N. Nikolay and G. I. Gabor, “Pathogenesis of Sjogren’s Syndrome,” Current Opinion in Rheumatology, Vol. 21, No. 5, 2009, pp. 465-470.
[8]	C. Vitali, S. Bombaridieri. R. Jonsson, et al., “Classification Criteria for Sjogren’s Syndrome: A Revised Version of the European Criteria Proposed by the American-European Consensus Group,” Annals of Rheumatic Disease, Vol. 61, No. 6, 2002, pp. 554-558. doi:10.1136/ard.61.6.554
[9]	P. B. Zeron, M. Ramos-Casals, A. Bove., et al., Predicting Adverse Outcomes in Primary Sjogren’s Syndrome: Identification of Prognostic Factors,” Rheumatology, Vol. 46, No. 8, 2007, pp. 1359-1362.
[10]	Y. Masaki and S. Sugai, “Lymphoproliferative Disorders in Sjogren’s Syndrome,” Autoimmunity Reviews, Vol. 3, No. 3, 2004, pp. 175-182.